GLUE
Income statement / Annual
Last year (2023), Monte Rosa Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Monte Rosa Therapeutics, Inc.'s net income was -$135.35 M.
See Monte Rosa Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$6.22 M |
$8.56 M |
$2.13 M |
$537,000.00 |
$72,000.00 |
| Gross Profit |
-$6.22 M |
-$8.56 M |
-$2.13 M |
-$537,000.00 |
-$72,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$111.27 M
|
$85.06 M
|
$57.16 M
|
$24.01 M
|
$7.35 M
|
| General & Administrative
Expenses |
$32.04 M
|
$27.32 M
|
$15.73 M
|
$4.01 M
|
$644,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$32.04 M
|
$27.32 M
|
$15.73 M
|
$4.01 M
|
$644,000.00
|
| Other Expenses |
$0.00 |
$0.00 |
-$960,000.00 |
-$7.68 M |
$276,000.00 |
| Operating Expenses |
$143.31 M |
$112.38 M |
$72.88 M |
$28.01 M |
$7.99 M |
| Cost And Expenses |
$143.31 M |
$112.38 M |
$72.88 M |
$28.01 M |
$7.99 M |
| Interest Income |
$9.33 M |
$3.76 M |
$46,000.00 |
$9,000.00 |
$12.00 |
| Interest Expense |
$0.00 |
$3.76 M |
$0.00 |
$0.00 |
$1,000.00 |
| Depreciation &
Amortization |
$6.22 M
|
$8.56 M
|
$2.13 M
|
$537,000.00
|
$72,000.00
|
| EBITDA |
-$137.09 M
|
-$99.94 M
|
-$70.75 M
|
-$27.47 M
|
-$7.67 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$8.30 M
|
$3.88 M
|
-$1.08 M
|
-$7.87 M
|
$254,000.00
|
| Income Before Tax |
-$135.01 M |
-$108.50 M |
-$73.96 M |
-$35.88 M |
-$7.74 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$338,000.00 |
-$3.88 M |
-$2.02 M |
$189,000.00 |
$277,000.00 |
| Net Income |
-$135.35 M |
-$104.62 M |
-$71.94 M |
-$36.07 M |
-$8.02 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.63 |
-2.22 |
-1.55 |
-0.82 |
-0.18 |
| EPS Diluted |
-2.63 |
-2.22 |
-1.55 |
-0.82 |
-0.18 |
| Weighted Average Shares
Out |
$51.40 M
|
$47.23 M
|
$46.54 M
|
$44.00 M
|
$44.00 M
|
| Weighted Average Shares
Out Diluted |
$51.40 M
|
$47.23 M
|
$46.54 M
|
$44.00 M
|
$44.00 M
|
| Link |
|
|
|
|
|
